MedDataX Logo

Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

NCT ID: NCT00904371

Last Updated: 2012-08-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

211 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks. Further on, the study will evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with arterial hypertention

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of essential arterial hypertension (BP\>140/90 mm HG or BP\>130/80 mm Hg for diabetic patients)
* at least an additional cardiovascular risk factor

Exclusion Criteria

* hypersensitivity to the active substance or to any of the excipients in any ACE inhibitor or angiotensin receptor blocker (ARB) available on the local market
* pregnancy and lactation
* diseases involving biliary obstruction
* severe liver impairment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site 24

Brežice, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 2

Brežice, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 12

Celje, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 16

Celje, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 17

Celje, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 1

Celje, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 33

Celje, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 18

Golnik, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 23

Golnik, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 29

Golnik, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 32

Golnik, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 15

Jesenice, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 4

Kranj, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 28

Litija, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 26

Ljubljana, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 35

Ljubljana, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 3

Ljubljana, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 6

Ljubljana, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 14

Maribor, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 22

Maribor, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 20

Murska Sobota, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 27

Murska Sobota, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 31

Murska Sobota, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 11

Novo Mesto, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 19

Novo Mesto, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 21

Novo Mesto, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 9

Novo Mesto, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 25

Sempeter, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 30

Sempeter, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 34

Sežana, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 10

Slovenj Gradec, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 36

Slovenj Gradec, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 13

Topolšica, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 5

Trbovlje, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 8

Trbovlje, , Slovenia

Site Status

Boehringer Ingelheim Investigational Site 7

Velenje, , Slovenia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Slovenia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.585

Identifier Type: -

Identifier Source: org_study_id